Compliance & Validation — Not documented by Atlas
Ask the vendor: Which compliance certifications (HIPAA, 21 CFR Part 11, SOC 2, GxP) do you hold?
Oncology-focused AI platform that reads longitudinal patient records to automate trial matching and chart abstraction at cancer centers.
Triomics, founded in 2021 and headquartered in New York, builds oncology-specific AI that reads the full longitudinal patient record — including unstructured notes — to support clinical trial matching, eligibility pre-screening, and chart abstraction. The company works with major academic cancer centers and raised a $22M Series B in May 2026. Its privacy policy documents how it handles HIPAA-regulated health data; Atlas found no vendor-held security certifications documented on its site.
50% — Partial coverage. Coverage score — how completely Atlas documents Triomics across 7 buyer-evaluation areas. Reflects available Atlas data, not solution quality.
Ask the vendor: Which compliance certifications (HIPAA, 21 CFR Part 11, SOC 2, GxP) do you hold?
cloud
Ask the vendor: What is your pricing model, and what drives total cost of ownership?
Ask the vendor: What is a realistic implementation timeline, and what onboarding support is included?
Mid-Size Biotech, Large Pharma, Academic / Research, Clinical Operations, Data Management, R&D Leadership
Natural Language Processing, Patient Recruitment
Series B, Founded 2021
Not captured in Atlas data — confirm directly. Excluded from the score above.
Who owns model outputs? Is our proprietary data used to train models others can access, and where does our data reside?
Can you share validation studies or benchmarks, explain how the model reaches its conclusions, and describe how bias and drift are monitored?